Nordberg Medical

What Nordberg Medical does

Nordberg Medical is a Swedish biotechnology and medical devices company founded in 2017, headquartered in Huddinge (with offices at Klarabergsviadukten 63, Stockholm) and operating manufacturing sites in Uppsala and Malmö. The company develops, manufactures, and commercializes PLLA (Poly-L-Lactic Acid)-based collagen biostimulators for the medical aesthetics market. Its flagship product, JULÄINE™, is a CE-marked injectable powered by the proprietary LASYNPRO™ technology (Lactic Acid Induced Synthesis of Collagen Protein), which uses high-purity PLLA microspheres to stimulate the body's own collagen production for natural-looking, long-lasting facial rejuvenation. Scientific collaborations with the Karolinska Institute and Research Institutes of Sweden (RISE) anchor clinical evidence development, supported by a pipeline of 30+ studies.

The company sells directly to aesthetic doctors, dermatologists, plastic surgeons, and medical aesthetics clinics through a field sales force operating from regional offices in Sweden, Germany (Frankfurt, Opernplatz 14), France (Paris), Italy (Milan), Spain (Madrid), and Hong Kong (Causeway Bay). Products are authorized in 35+ countries with employees in 18, and the company maintains wholly-owned regional entities in Germany (Nordberg Medical GmbH) and Spain (Nordberg Medical S.L.). Pricing is quote-based and not publicly disclosed, with a one-time B2B sales model rather than subscriptions or licensing. The GTM motion is event-driven and clinician-led, with presence at conferences such as AMWC and proprietary training events including a 113-attendee Summer Summit 2025.

Nordberg Medical is privately held with no disclosed venture or private equity funding, no parent company, and no disclosed M&A activity. Headcount has tripled within roughly one year to 100+ employees. Regulatory progress includes ISO 13485:2016 certification (2021), Brazilian market approval (2025), and FDA registration in progress for a future US launch, positioning the company for continued geographic and commercial expansion from a Europe-and-APAC base into the Americas.

Name

Nordberg Medical

Legal name

Nordberg Medical AB

Website

https://nordbergmedical.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

101–250 employees

Short description

Nordberg Medical is a Swedish biotech company that develops and commercializes PLLA-based collagen biostimulator injectables (JULÄINE™) powered by its proprietary LASYNPRO™ technology, selling directly to aesthetic doctors and clinics across Europe and APAC.

Ownership category

akta.pro rank

Product category

Medical Aesthetics Injectables

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Biological Product (except Diagnostic) Manufacturing (325414), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841), Perfumes, Cosmetics & Other Toilet Preparations (2844), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cosmetic Dermatology (Aesthetic Injectables) (HLAKACAE)

akta.pro secondary industry

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)

Keywords

• Collagen biostimulators
• Medical aesthetics biomaterials
• PLLA injectables
• Regenerative aesthetic devices
• Anti-aging medical solutions

Headquarters

HQ city

Huddinge

HQ country

Sweden

HQ region

Europe

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain

Revenue model

1. Product Sales (B2B): Revenue generated through direct sales of medical biomaterial products to healthcare professionals, clinics, and aesthetic medicine practitioners across Europe and APAC regions.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels7 records

Core offering

Nordberg Medical develops and manufactures PLLA-based collagen biostimulator injectables for the medical aesthetics market. Its flagship product JULÄINE™ uses proprietary LASYNPRO™ technology (Poly-L-Lactic Acid microspheres) to stimulate the body's natural collagen production, delivering gradual, long-lasting facial rejuvenation. Products are sold directly to aesthetic doctors, dermatologists, and clinics across Europe and APAC.

Product overview

Nordberg Medical is a Swedish biotechnology and medical devices company that develops, manufactures, and commercializes advanced medical biomaterials. The company's flagship product is JULÄINE™, a CE-marked injectable collagen biostimulator powered by the proprietary LASYNPRO™ technology. JULÄINE™ is designed for facial aesthetic correction and works by stimulating the body's natural collagen production through poly-L-lactic acid (PLLA) microspheres, delivering gradual, long-lasting, and natural-looking results.

Differentiator

Problem solved

Functional benefit

Brands

• JULÄINE: Nordberg Medical's flagship brand in medical aesthetics: a next-generation collagen biostimulator that regenerates collagen to naturally smooth wrinkles and tighten skin. Developed and manufactured in Sweden, CE-marked injectable harnessing proprietary LASYNPRO technology.
• Nordberg Medical Institute

Products and services

• JULÄINE™ A next-generation Poly-L-Lactic Acid (PLLA) based collagen biostimulator injectable that activates the body's natural collagen production through high-purity PLLA microspheres, delivering natural-looking facial rejuvenation, wrinkle reduction, skin tightening, and long-lasting aesthetic results. CE-marked, ISO 13485 manufactured, designed for use by aesthetic doctors, dermatologists, and plastic surgeons in clinical settings.

Quantifiable outcome

• Product authorized in over 35 countries with presence in Europe and APAC
• +1 more outcomes

Named customers5 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered core.

• Karolinska InstitutecoreStrategic or Co-development PartnerScientific collaboration with Karolinska Institute for research and development in regenerative aesthetics and collagen stimulation technology. Partnership leverages academic research capabilities to support clinical evidence development.
• Research Institutes of Sweden (RISE)coreStrategic or Co-development PartnerCollaborative partnership for whitepaper development and scientific publications on PLLA technology and collagen stimulation. RISE provides research institute credibility and technical validation for the company's proprietary technology.

Scale indicators4 records

Recent moves13 records

Expansion highlights6 records

Direct peers

• Galderma: Galderma manufactures Sculptra, the leading PLLA-based collagen biostimulator and the most direct competitor to Nordberg's JULÄINE in facial rejuvenation aesthetics. It competes head-to-head with Nordberg on mechanism of action, target customers (aesthetic practitioners), and distribution channels globally.
• Merz Aesthetics: Merz Aesthetics markets Radiesse (calcium hydroxylapatite) and Belotero (HA fillers) to aesthetic practitioners, directly competing in the collagen biostimulation and dermal filler space where JULÄINE is positioned. Comparable in targeting the same clinical decision-makers and clinic channels.
• Sinclair Pharma (acquired by Huadong Medicine): Sinclair Pharma developed Ellansé, a collagen-stimulating dermal filler with PCL microspheres, directly competing with Nordberg's PLLA-based JULÄINE in the biostimulator category. Comparable target customer (aesthetic doctors) and Europe-led commercial footprint.
• Croma-Pharma: Croma-Pharma is an Austrian-based aesthetics company producing HA fillers, PRP kits, and biostimulator products sold through aesthetic practitioners in Europe. Comparable in being a Europe-headquartered, privately-held aesthetics manufacturer targeting the same clinical segment.
• TEOXANE Laboratories: TEOXANE manufactures a portfolio of HA-based dermal fillers and skin boosters distributed to aesthetic practitioners worldwide. Competes with Nordberg in the facial rejuvenation injectable space with overlapping customer segments and similar European commercial roots.

Broad incumbents

• AbbVie (Allergan Aesthetics): AbbVie's Allergan Aesthetics division sells Juvéderm (HA fillers), Botox, and CoolSculpting, making it a broad incumbent in medical aesthetics. Overlaps with Nordberg in facial rejuvenation injectables and shares the same aesthetic practitioner channel.
• Evolus: Evolus markets Jeuveau, a neurotoxin for aesthetic indications, and competes for the same aesthetic medicine practitioners that Nordberg targets. While the modality differs, both companies are growth-stage aesthetic pure-plays with similar channel dynamics.
• Revance Therapeutics: Revance commercializes the DAXXIFY neurotoxin and the RHA line of HA fillers in aesthetics. Comparable as a US-listed aesthetics-focused company pursuing the same physician customer base that Nordberg addresses with JULÄINE.

Regional players

• Hugel (Charmmed): Hugel is a Korean aesthetics and botulinum toxin manufacturer with strong APAC distribution that competes in the broader injectable aesthetics category. Relevant as a regional peer in APAC where Nordberg operates its Hong Kong regional headquarters.

Others

• Karolinska Institute (SciBase collaboration reference): Karolinska Institute is a research partner of Nordberg rather than a competitor, but is a relevant ecosystem participant given the official collaboration on regenerative aesthetics R&D and shared Swedish science cluster positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@NordbergMedical
• LinkedInlinkedin.com/company/nordberg-medical
• Instagraminstagram.com/nordbergmedical
• Facebookfacebook.com/nordbergmedical

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nordberg Medical